Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Intravenous Lidocaine and Acute Rehabilitation
This study has been completed.
Sponsors and Collaborators: Outcomes Research Consortium
University Hospital of Liege
Information provided by: Outcomes Research Consortium
ClinicalTrials.gov Identifier: NCT00330941
  Purpose

Background: Intravenous infusion of lidocaine may decrease postoperative pain and speed return of bowel function. We therefore tested the hypothesis that including perioperative lidocaine infusion improves recovery from laparoscopic colectomy and shortens the duration of hospitalization.

Methods: Forty patients scheduled for laparoscopic colectomy were randomly allocated to receive intravenous lidocaine (bolus injection of 1.5 mg.kg-1 lidocaine at induction of anesthesia, then a continuous infusion of 2 mg.kg-1.h-1 intraoperatively and 1.33 mg.kg-1.h-1 for 24 h postoperatively) or an equal volume of saline. All patients received similar intensive postoperative rehabilitation. Postoperative pain scores, opioid consumption, and fatigue scores were measured. Times to first flatus, defecation, and hospital discharge were recorded. Postoperative endocrine (cortisol and catecholamines) and metabolic (leucocytes, C-reactive protein, and glucose) responses were measured for 48 h. Data (median [25%-75% interquartile range] Saline vs Lidocaine groups) were analyzed using Mann-Whitney tests. P<0.05 was considered statistically significant.


Condition Intervention Phase
Pain, Postoperative
Opioid Consumption, Postoperative
Postoperative Fatigue
Drug: lidocaine
Phase IV

MedlinePlus related topics: Anesthesia Rehabilitation
Drug Information available for: Lidocaine
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Intravenous Lidocaine Infusion Improves Outcome After Laparoscopic Colectomy

Further study details as provided by Outcomes Research Consortium:

Primary Outcome Measures:
  • Sevoflurane consumption
  • Pain scores
  • abdominal comfort
  • fatigue scores

Secondary Outcome Measures:
  • bowel function
  • hospital stay
  • endocrine and metabolic responses

Estimated Enrollment: 45
Study Start Date: January 2003
Estimated Study Completion Date: December 2004
  Eligibility

Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ASA I-III
  • non-malignant disease

Exclusion Criteria:

  • greater than 70 years
  • history of gastro-duodenal peptic ulcer or renal failure (contraindications to the use of nonsteroidal anti-inflammatory drug)
  • hepatic insufficiency
  • psychiatric disorder
  • steroid treatment
  • chronic treatment with opioid
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00330941

Locations
Belgium
CHU de Liège, University of Liège
Liege, Belgium, B-4000
Sponsors and Collaborators
Outcomes Research Consortium
University Hospital of Liege
Investigators
Study Director: Jean Joris, MD, PhD Department of Anesthesia and Intensive Care Medicine, CHU de Liège, University of Liège, Belgium
  More Information

Study ID Numbers: Joris, Lidocaine Outcomes
Study First Received: May 25, 2006
Last Updated: October 16, 2008
ClinicalTrials.gov Identifier: NCT00330941  
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment

Study placed in the following topic categories:
Signs and Symptoms
Fatigue
Postoperative Complications
Lidocaine
Pain
Pain, Postoperative

Additional relevant MeSH terms:
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Cardiovascular Agents
Anti-Arrhythmia Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions
Anesthetics, Local

ClinicalTrials.gov processed this record on January 15, 2009